16 September 2026 editorial review · Item
Aspect Biosystems bioprinted islet tissue (ex-Novo Nordisk platform): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: Aspect's 2022 poster used rat islets and a chemical diabetes model; the later-acquired hypoimmune component has no combined human proof. Current pipeline stage is undisclosed. Removed the false exclusive Sana human benchmark.
- Programme/sponsor/conference source boundary: Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes (manufacturer); "816-P: Bioprinted Allogeneic Islet-Containing Implants Normalize Blood Glucose Control in Diabetic Rat Models without Immune Suppression" (conference); Aspect Biosystems to Present on Pancreatic Tissue Therapeutic at American Diabetes Association 82nd Scientific Sessions (manufacturer); Pipeline of Bioprinted Tissue Therapeutics — Aspect Biosystems (manufacturer).